Skip to main content
Glama

Osv

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The annotations already declare read-only, idempotent, and open-world behavior, but the description goes well beyond them. It discloses internal cascading lookups, graceful degradation when GLEIF or OpenFIGI is unavailable, explicit `unresolved` reporting, `figi_candidates` on ambiguous matches, and source-labelled identifiers. No contradiction with the annotations exists.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is long and dense, especially the company block, but it is front-loaded with examples and the core 'Use FIRST' rule. Every detail serves a purpose, though it could be tightened or bulleted for easier scanning.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries full responsibility for explaining return behavior. It covers key fields (CIK, ticker, LEI, FIGI, RxCUI, ingredient, brand), ambiguity handling via `figi_candidates`, explicit `unresolved` output, and fallback behavior when external sources are unavailable. For a two-type resolver, this is complete.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema already covers both parameters, but the description adds substantive meaning: it introduces ISIN as an accepted company input, clarifies that trailing security-class words like 'revenue bonds' will not match, and details what each entity type returns. This is valuable semantic information beyond the schema.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description states a specific verb and resource: resolving user-spoken names to canonical identifiers. It enumerates the supported entity types (company and drug), gives concrete query examples, and distinguishes the tool from siblings by saying 'Use FIRST whenever you have a name but need an ID' and noting these are 'identifiers other tools require as input.'

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

It explicitly says when to use the tool ('Use FIRST whenever you have a name but need an ID') and gives strong input guidance, such as passing only the exact entity name and not a full noun phrase. However, it does not name sibling alternatives or state when not to use this tool, so it stops short of a 5.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Osv toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A4/5.0
Disambiguation3/5

Several tools have overlapping purposes: ask_pipeworx, ask_pipeworx_beta, and ask_pipeworx_grounded are very similar, as are the suite of polymarket_* tools. While descriptions help differentiate, an agent may struggle to choose the correct one without careful reading.

Naming Consistency3/5

All tool names use snake_case, but they mix verb-first patterns (ask_pipeworx, compare_entities, validate_claim) with noun-first patterns (bet_research, entity_profile, pipeworx_feedback). This inconsistency makes it harder to guess tool names by convention.

Tool Count3/5

35 tools is on the high side but not unreasonable for a platform covering vulnerability queries, data retrieval, prediction markets, and utilities. However, the server name 'Osv' suggests a narrow focus, making the large count feel bloated.

Completeness4/5

The tool set covers a wide range of operations: querying data, comparing entities, managing user data, monitoring subscriptions, and even onboarding. Minor gaps exist (e.g., no direct API for updating user profiles), but overall it is well-rounded for its domain.

Resources